Motley Fool |
Why Amarin's Latest News Caused Shares to Crash 13% Today
Motley Fool Amarin delivered welcome news to investors in September when it reported that a cardiovascular outcomes trial showed its only commercial drug, Vascepa, reduces the risk of heart attack, stroke, and cardiovascular-related deaths. A woman shrugs in front ... |
from news - Google News https://ift.tt/2E21JkJ
0 comments:
Post a Comment